European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CX24--Polish Version

Paradowska, Dominika; Tomaszewski, Krzysztof A.; Bałajewicz-Nowak, Marta; Bereza, Krzysztof; Tomaszewska, Iwona M.; Paradowski, Jan; Pityński, Kazimierz; Skotnicki, P.; Greimel, Eva; Bottomley, Andrew

doi:10.1037/t72388-000

Search citation statements

Order By: Relevance

Paper Sections

Select...

Questionnaire-cervical Cancer Module (Eortc Qlq Cx-24)1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the use of item generation and cognitive testing across samples of women from nine European countries, Australia, Brazil, Korea and Taiwan and international expert panel review enhance the instrument's content validity [49]. The CX-24 has been validated in South Asian [50], Korean [51], Chinese [52], Polish [53] and South African [54] samples. (Table 4).…”

Section: Questionnaire-cervical Cancer Module (Eortc Qlq Cx-24)mentioning

confidence: 99%

Assessment of sexual difficulties associated with multi-modal treatment for cervical or endometrial cancer: A systematic review of measurement instruments

White

Sangha

Lucas

et al. 2016

Gynecologic Oncology

View full text Add to dashboard Cite

Findings suggest that the Female Sexual Function Index (FSFI) remains the most robust sexual morbidity outcome measure, for research or clinical use, in sexually active women treated for cervical or endometrial cancer. Development of an instrument that measures sexual dysfunction in women who are infrequently/not sexually active due to treatment consequences is still required to identify women in need of sexual rehabilitation.

show abstract